Skip to main content
. Author manuscript; available in PMC: 2013 Feb 28.
Published in final edited form as: Clin Pharmacol Ther. 2011 Feb 23;89(4):562–570. doi: 10.1038/clpt.2010.313

Figure 2.

Figure 2

Effect of CYP3A induction and inhibition on oral alfentanil (d3-ALF) plasma concentrations. Subjects received nothing (controls, ●), rifampin (▲), grapefruit juice (■), or ketoconazole (▼). Results are shown as mean ± SD (n=6); some SD are omitted for clarity. The d3-ALF dose was 4.0 mg, except after ketoconazole pretreatment (1.0 mg d3-ALF). Panels A–C show measured concentrations, and panels D–F show dose-adjusted concentrations. Panels A and D show results for sequential IV d0-ALF and oral d3-ALF (separated by 3 hr) administration, panels B and E show results for simultaneous IV d0-ALF and oral d3-ALF administration, and panels C and E show the results superimposed (solid lines and symbols, and open symbols and dotted lines represent sequential and simultaneous dosing, respectively).